Research analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Free Report) in a research note issued on Tuesday. The firm set a “sell” rating on the medical device company’s stock.
NeuroMetrix Stock Down 5.9 %
Shares of NeuroMetrix stock opened at $3.81 on Tuesday. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $6.00. The stock has a market cap of $7.66 million, a PE ratio of -0.60 and a beta of 2.28. The business has a fifty day simple moving average of $3.61 and a 200-day simple moving average of $3.84.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. The business had revenue of $0.77 million for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%.
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
Further Reading
- Five stocks we like better than NeuroMetrix
- Stock Dividend Cuts Happen Are You Ready?
- How Much Can You Make in Stocks in One Month?
- Transportation Stocks Investing
- This Is the Top Large-Cap Stock Insiders Are Buying
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.